Top 8 Companies in the Global AI in Clinical Trials Market

The global AI in clinical trials market was valued at USD 1.80 billion in 2023, driven by rising requirements to overcome data limitations worldwide. It is expected to grow at a CAGR of 14.00% during the forecast period 2024-2032 and attain a market value of USD 5.85 billion by 2032.

AI technology, combined with big data, can tackle major obstacles in clinical trials by processing and examining large volumes of data. AI and advanced analytics can enhance productivity in clinical R&D by merging trial phases, developing patient-focused endpoints, and examining real world data. Increased participation of AI in drug research and development is expected to fuel market growth. Additionally, the market is impacted by the increasing emphasis on diversity and inclusivity.

Technological advancements and the increasing adoption of artificial intelligence (AI) are significantly driving growth in drug research and development. The market is continuously witnessing how AI and data analytics are streamlining clinical trials by reducing both time and costs, enhancing the efficiency of drug development, and tackling data complexities. These innovations are improving the speed at which medications reach the market and optimising technological investments in the biopharmaceutical sector, further accelerating market growth.

Major Companies Shaping the AI in Clinical Trials Market in 2024

1.    Unlearn.ai, Inc.

Founded in 2017, Unlearn.ai is a US-based AI company revolutionising clinical trials through advanced machine learning. The company uses generative AI to create digital twin models that simulate patient progressions, improving clinical trial efficiency and reducing sample size requirements. For instance, in July 2024, the company showcased two poster sessions at the Alzheimer's Association International Conference (AAIC) in collaboration with Johnson & Johnson and AbbVie, demonstrating AI’s potential in accelerating Alzheimer's trials and reducing treatment effect variance. This innovation is set to significantly impact the AI-driven clinical trials market by enhancing trial design, reducing costs, and expediting drug development, particularly in Alzheimer's disease research.

2.    Saama

Established in 1997 and headquartered in the United States, Saama is a leading AI company focused on transforming life sciences through data-driven insights. It was recently awarded "Best AI-Based Solution for Life Sciences" at the AI Breakthrough Awards 2024, recognising its innovative work in clinical trials. Saama's AI platforms enable data integration, real-time analytics, and decision-making to optimise clinical trial processes. This recognition further strengthens Saama’s position in the clinical trials market, driving growth by enhancing trial success rates, reducing timelines, and providing deeper insights into clinical data to improve therapeutic development.

3.    Antidote Technologies, Inc.

Antidote Technologies, a leader in matching patients with clinical trials, leverages AI and machine learning to streamline the clinical trial recruitment process. By using AI algorithms to connect patients with the right trials based on their medical profiles, Antidote enhances recruitment efficiency and accelerates trial timelines. As the demand for faster and more efficient trials grows, Antidote's solutions are poised to have a significant impact on the non-viral transfection system and broader AI in the clinical trials market by improving recruitment strategies and reducing overall trial costs.

4.    Phesi

Phesi, established as a global leader in patient-centric data analytics, harnesses AI to revolutionise clinical trial design and patient recruitment. For instance, in February 2024, Phesi announced its Trial Accelerator Platform reached a milestone, incorporating data from over 100 million patients, including detailed Digital Patient Profiles (DPP) across 4,000 indications. This AI-driven platform offers highly accurate simulations, enhancing trial planning and reducing patient recruitment timelines. The vast, patient-centric dataset will drive innovation in clinical trials, accelerating AI adoption for predictive trial modelling and enhancing market growth in the coming years.

5.    Deep6.ai

Deep6.ai, based in the United States, focuses on using AI to mine clinical and genomic data to improve clinical trial recruitment and design. For instance, in September 2023, it launched its genomics module, which uses AI to mine electronic medical record (EMR) and genetic reports to precisely match patients to clinical trials based on their complete genomic profile. This precision-matching technology is set to significantly reduce the time spent on patient recruitment, improve trial design, and enhance overall clinical trial efficiency. This innovation is expected to drive the growth of the AI-powered clinical trials market by improving patient stratification and trial success rates.

6.    Innoplexus

Founded in 2011, Innoplexus is a Germany-based AI company providing data-driven solutions in the pharmaceutical and biotech sectors. The company’s AI platforms are used for drug discovery, clinical trials, and market access. For instance, in June 2024, Innoplexus partnered with the Experimental Drug Development Centre (EDDC) in Singapore to use AI for novel drug indication identification. This collaboration enhances the AI clinical trials landscape by integrating AI with scientific expertise to accelerate the discovery and development of new therapeutics. The partnership’s success will have a profound impact on AI integration in clinical trial processes, particularly in precision medicine.

7.    Intelligencia AI

Intelligencia AI is an emerging player in the AI clinical trials market, focusing on enhancing the drug development process through artificial intelligence and machine learning. Its solutions provide actionable insights into clinical trial data, improving decision-making and trial outcomes. Although specific recent news is not available, Intelligencia’s growing influence in AI-driven clinical trials is expected to increase market competition, driving further innovations and accelerating the adoption of AI technologies for clinical trial optimisation.

8.    Median Technologies

Founded in 2002, Median Technologies, headquartered in France, is a leader in AI-powered diagnostic solutions. Its proprietary software, eyonis LCS, aims to improve lung cancer screening accuracy using AI/ML-powered analysis of low-dose CT scans. For instance, in 2024, Median’s eyonis LCS successfully met key endpoints in its pivotal study, supporting its potential for regulatory approval. This success reinforces the growing role of AI in enhancing clinical trial designs, patient diagnostics, and therapeutic development, positioning Median to play a pivotal role in shaping the future of clinical trials in oncology.